Key Metrics
Total funding
$272M
As of Jul 31, 2026Value Add Pulse research
Company Snapshot
Triveni Bio is a Biotech company, based in Waltham, Massachusetts, founded 2023. Total funding $272M (As of Jul 31, 2026).
Recent changes
- Jul 31, 2026Jul 31, 2026First reported total funding: $272M Value Add Pulse enrichment
- Jun 18, 2026Jun 18, 2026Triveni Bio Raises $65M for Antibody Therapeutics in Immunology Pulse story
- Jun 17, 2026Jun 17, 2026Raised $65M Series C Triveni Bio
- Jun 17, 2026Jun 17, 2026Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics Pulse story
Funding History
1 event · sources dated per row| Date | Event | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jun 17, 2026 | Series C | $65M | — | Triveni Bio |
Investors
Latest Pulse
- Jun 18, 2026Triveni Bio Raises $65M for Antibody Therapeutics in ImmunologyTriveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.→
- Jun 17, 2026Triveni Bio Raises $65M for Antibody-Based Immunology TherapeuticsTriveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.→
Coverage Timeline
newest firstAll Coverage
FUNDING$65M
Triveni Bio Raises $65M for Antibody Therapeutics in Immunology
Triveni Bio raised $65 million, co-led by Ascenta Capital and Janus Henderson Investors, to advance antibody-based therapeutics for immunological and inflammatory diseases. The round is a reminder that biotech capital is still flowing to differentiated science even in an AI-dominated market.
Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics
FUNDING$65M
Triveni Bio Raises $65M for Antibody-Based Immunology Therapeutics
Triveni Bio raised $65 million co-led by Ascenta Capital and Janus Henderson to advance antibody-based therapeutics targeting immunological diseases. The round is part of a biotech rebound that's running alongside the AI-infrastructure boom rather than being crowded out by it.
Related Companies
Triveni Bio FAQ
How much has Triveni Bio raised?
Triveni Bio has raised $272M in total funding (As of Jul 31, 2026, Value Add Pulse research).
Who are Triveni Bio's investors?
Triveni Bio's investors include Ascenta Capital, Atlas Venture, Cormorant Asset Management, Deep Track Capital, Fidelity Investments, and 3 more (As of Jul 31, 2026).
Sources & methodologyshow
Where these figures come from
- Triveni Bioprimary source1 fact
- Value Add Pulse researchValue Add VC data1 fact
Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.